Jain Hasmukh, Rengaraj Karthik, Sharma Vibhor, Bonda Avinash, Chanana Raajit, Thorat Jayashree, Ronghe Ashwini, Biswas Sanjay, Nayak Lingaraj, Tembhare Prashant, Subramnian Papagudi, Shetty Dhanalaxmi, Patkar Nikhil, Bagal Bhausaheb, Sengar Manju
Department of Medical Oncology, Tata Memorial Hospital, affiliated to Homi Bhabha National Institute, Mumbai, India.
Medical Resident, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY.
JCO Glob Oncol. 2020 Nov;6:1684-1695. doi: 10.1200/GO.20.00240.
Infections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high incidence of multidrug-resistant (MDR) organisms, high incidence of fungal pneumonia at baseline, and significant delay before initiation of chemotherapy. We aimed to look at contemporary infections and infection-related mortality and analyze the patterns of infections.
This retrospective study was conducted at a large tertiary care oncology center in India. Patients with newly diagnosed AML who were older than age 15 years, considered fit for intensive therapy, and treated in the general wards of the adult hematolymphoid unit from March 1, 2014, until December 31, 2015, were included.
One hundred twenty-one patients were treated during the study period. The most common presenting complaint was fever (85%). The focus of infection at presentation was found in 63% of patients, with respiratory infection being the most common (47%). MDR organisms were isolated in 55% of patients during induction from various foci. was the most common blood culture isolate (42.9%). Fungal pneumonia was diagnosed in 55% of patients during induction despite antifungal prophylaxis. Treatment-related mortality was 10.7% in all phases, with an induction mortality rate of 7.4%. Complete remission was attained in 69% of patients. Of all patients who received induction chemotherapy, 74% completed all three consolidation cycles. The 121 patients were followed up for a median period of 53 months. Four-year event-free survival was 35.8%, and 4-year overall survival was 41.5%.
Infections and infection-related mortality are major challenges during AML induction. Gram-negative MDR and fungal infections are particularly common in our region.
感染仍是急性髓系白血病(AML)治疗中的一项重大挑战。文献报道的诱导相关死亡率在临床试验中约<5%。然而,实际情况有所不同,尤其是在发展中国家,鉴于多重耐药(MDR)菌的高发病率、基线时真菌性肺炎的高发病率以及化疗开始前的显著延迟。我们旨在研究当代感染情况及感染相关死亡率,并分析感染模式。
本回顾性研究在印度一家大型三级肿瘤护理中心进行。纳入2014年3月1日至2015年12月31日期间在成人血液淋巴科普通病房接受治疗、年龄大于15岁、被认为适合强化治疗的新诊断AML患者。
研究期间共治疗121例患者。最常见的主诉是发热(85%)。63%的患者在就诊时发现感染病灶,其中呼吸道感染最为常见(47%)。诱导治疗期间,55%的患者从不同病灶分离出MDR菌。 是最常见的血培养分离菌(42.9%)。尽管进行了抗真菌预防,仍有55%的患者在诱导治疗期间被诊断为真菌性肺炎。各阶段治疗相关死亡率为10.7%,诱导死亡率为7.4%。69%的患者实现完全缓解。在所有接受诱导化疗的患者中,74%完成了全部三个巩固周期。对121例患者进行了中位53个月的随访。4年无事件生存率为35.8%,4年总生存率为41.5%。
感染及感染相关死亡率是AML诱导治疗期间的重大挑战。革兰氏阴性MDR菌感染和真菌感染在我们地区尤为常见。